ssmuБюллетень сибирской медициныBulletin of Siberian Medicine1682-03631819-3684Siberian State Medical University, the Ministry of Healthcare of the Russian Federation10.20538/1682-0363-2023-4-48-56ssmu-5417Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL PAPERSРаспространенность некоторых терапевтических заболеваний в зависимости от уровней адипокинов у людей до 45 летPrevalence of some internal diseases depending on the adipokine level in people under 45 years of agehttps://orcid.org/0000-0003-2268-4186КаштановаЕ. В.KashtanovaE. V.

Каштанова Елена Владимировна – д-р биол. наук, доцент, зав. лабораторией клинических биохимических и гормональных исследований терапевтических заболеваний

630089, г. Новосибирск, ул. Бориса Богаткова 175/1

175/1, Bogatkova Str., Novosibirsk, 630089

elekastanova@yandex.ruhttps://orcid.org/0000-0002-3538-0280ПолонскаяЯ. В.PolonskayaYa. V.

Полонская Яна Владимировна – д-р биол. наук, ст. науч. сотрудник, лаборатория клинических биохимических и гормональных исследований терапевтических заболеваний

630089, г. Новосибирск, ул. Бориса Богаткова 175/1

175/1, Bogatkova Str., Novosibirsk, 630089

yana-polonskaya@yandex.ruhttps://orcid.org/0000-0001-9270-9188ЩербаковаЛ. В.ShcherbakovaL. V.

Щербакова Лилия Валерьевна – ст. науч. сотрудник, лаборатория клинико-популяционных и профилактических исследований терапевтических и эндокринных заболеваний

630089, г. Новосибирск, ул. Бориса Богаткова 175/1

175/1, Bogatkova Str., Novosibirsk, 630089

9584792@mail.ruhttps://orcid.org/0000-0002-0436-2549ШрамкоВ. С.ShramkoV. S.

Шрамко Виктория Сергеевна – канд. мед. наук, науч. сотрудник, лаборатория клинических биохимических и гормональных исследований терапевтических заболеваний

630089, г. Новосибирск, ул. Бориса Богаткова 175/1

175/1, Bogatkova Str., Novosibirsk, 630089

nosova@211.ruhttps://orcid.org/0000-0003-0484-6540СтахнёваЕ. М.StakhnevaE. M.

Стахнёва Екатерина Михайловна – канд. биол. наук, ст. науч. сотрудник, лаборатория клинических биохимических и гор- мональных исследований терапевтических заболеваний

630089, г. Новосибирск, ул. Бориса Богаткова 175/1

175/1, Bogatkova Str., Novosibirsk, 630089

stahneva@yandex.ruhttps://orcid.org/0000-0001-7875-1566ХудяковаА. Д.KhudyakovaA. D.

Худякова Алена Дмитриевна – зав. лабораторией генетических и средовых детерминант жизненного цикла человека

630089, г. Новосибирск, ул. Бориса Богаткова 175/1

175/1, Bogatkova Str., Novosibirsk, 630089

alene.elene@gmail.comhttps://orcid.org/0000-0001-7350-534XСадовскийЕ. В.SadovskiE. V.

Садовский Евгений Викторович – мл. науч. сотрудник, лаборатория клинических биохимических и гормональных исследований терапевтических заболеваний

630089, г. Новосибирск, ул. Бориса Богаткова 175/1

175/1, Bogatkova Str., Novosibirsk, 630089

stinger000@mail.ruhttps://orcid.org/0000-0002-2470-2133ДенисоваД. В.DenisovaD. V.

Денисова Диана Вахтанговна – д-р мед. наук, гл. науч. сотрудник, лаборатории профилактической медицины

630089, г. Новосибирск, ул. Бориса Богаткова 175/1

175/1, Bogatkova Str., Novosibirsk, 630089

denisovadiana@gmail.comhttps://orcid.org/0000-0002-4936-8362РагиноЮ. И.RaginoYu. I.

Рагино Юлия Игоревна – д-р мед. наук, член-корр. РАН, руководитель 

630089, г. Новосибирск, ул. Бориса Богаткова 175/1

175/1, Bogatkova Str., Novosibirsk, 630089

ragino@mail.ruНаучно-исследовательский институт терапии и профилактической медицины (НИИТПМ) – филиал Института цитологии и генетики Сибирского отделения Российской академии наук (ИЦиГ СО РАН)РоссияResearch Institute of Internal and Preventive Medicine – Branch of the Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of SciencesRussian Federation2023220120242244856Copyright © Каштанова Е.В., Полонская Я.В., Щербакова Л.В., Шрамко В.С., Стахнёва Е.М., Худякова А.Д., Садовский Е.В., Денисова Д.В., Рагино Ю.И., 20242024Каштанова Е.В., Полонская Я.В., Щербакова Л.В., Шрамко В.С., Стахнёва Е.М., Худякова А.Д., Садовский Е.В., Денисова Д.В., Рагино Ю.И.Kashtanova E.V., Polonskaya Y.V., Shcherbakova L.V., Shramko V.S., Stakhneva E.M., Khudyakova A.D., Sadovski E.V., Denisova D.V., Ragino Y.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://bulletin.ssmu.ru/jour/article/view/5417

Цель – изучить встречаемость некоторых распространенных терапевтических заболеваний у молодых людей трудоспособного и детородного возраста в зависимости от уровней адипокинов.

Материалы и методы

Материалы и методы. В исследование включено 1 340 человек в возрасте 25–44 лет. Методом мультиплексного анализа определены уровни лептина, адипонектина, адипсина, липокалина-2, ингибитора активатора плазминогена-1 (ИАП-1) и резистина. Изучены: гиперхолестеринемия липопротеинов низкой плотности (гиперХС-ЛНП), ишемическая болезнь сердца (ИБС), сахарный диабет 2-го типа (СД2), артериальная гипертензия (АГ), почечная дисфункция (ПД), хронический бронхит (ХБ).

Результаты

Результаты. С увеличением уровня адипонектина распространенность определенной ИБС возрастает в 8,6 раз. Самый высокий квартиль уровня адипсина характеризуется увеличением распространенности гиперХС-ЛНП на 12,9%, АГ на 3,9% и ПД на 17,9%. Квартили липолкалина-2 показали более высокую распространенность гиперХС-ЛПН, АГ и ПД в Q4 по сравнению с Q1. Распространенность ХБ ассоциирована со снижением уровня липокалина-2 и выше в Q1 на 35,9%, в сравнении с Q4. В квартилях ИАП-1 встречаемость СД2 и гиперХС-ЛНП в 2 и 1,5 раза соответственно выше, а ПД в 2,5 раза ниже в Q4, чем в Q1. В квартилях резистина на 13–38% увеличивается распространенность гиперХС-ЛНП, АГ, ПД. На 20% снижается распространенность хронического бронхита в Q4 по сравнению с Q1. Встречаемость гиперХС-ЛНП и ПД была выше в Q4 лептина.

Заключение

Заключение. Результаты свидетельствуют о необходимости дальнейших исследований, направленных на изучение молекулярных механизмов, лежащих в основе эффектов адипокинов, что позволит найти комбинированный подход, направленный на восстановление нормальных физиологических уровней адипокинов. Это может дать положительный эффект при изученных терапевтических заболеваниях.

The aim was to study the prevalence of some common internal diseases in young people of working and childbearing age, depending on the levels of adipokines.

Materials and methods

Materials and methods. The study included 1,340 people aged 25–44 years. The levels of leptin, adiponectin, adipsin, lipocalin-2, plasminogen activator inhibitor-1 (PAI-1), and resistin were determined by the multiplex analysis. Low-density lipoprotein hypercholesterolemia (LDL hypercholesterolemia), coronary artery disease (CAD), type 2 diabetes mellitus (T2DM), arterial hypertension (AH), renal dysfunction (RD), and chronic bronchitis (CB) were studied.

Results

Results. With an increase in the level of adiponectin, the prevalence of CAD increased by 8.6 times. The highest quartile of the adipsin level was characterized by an increase in the prevalence of LDL hypercholesterolemia by 12.9%, AH by 3.9%, and RD by 17.9%. The quartiles of lipolkalin-2 showed higher prevalence of LDL hypercholesterolemia, AH, and RD in Q4 compared to Q1. The prevalence of CB was associated with a decrease in the level of lipocalin-2 and was higher by 35.9% within Q1 compared to Q4. In the quartiles of PAI-1, the prevalence of T2DM and LDL hypercholesterolemia was 2 and 1.5 times higher, respectively, and the prevalence of RD was 2.5 times lower in Q4 than in Q1. In quartiles of resistin, the prevalence of LDL hypercholesterolemia, AH, and RD increased by 13–38%, while the prevalence of CB decreased by 20% in Q4, compared to Q1. The prevalence of LDL hypercholesterolemia and RD was higher within Q4 of leptin.

Conclusion

Conclusion. The results indicate the need for further research aimed at studying the molecular mechanisms underlying the effects of adipokines. This will allow to find a combined approach to restoring normal physiological levels of adipokines, which can have a positive effect in the studied internal diseases.

терапевтические заболеванияадипокиныадипонектинлипокалин-2резистинinternal diseasesadipokinesadiponectinlipocalin-2resistinСтатья подготовлена в рамках государственного задания «Эпидемиологический мониторинг состояния здоровья населения и изучение молекулярно-генетических и молекулярно-биологических механизмов развития распространенных терапевтических заболеваний в Сибири для совершенствования подходов к их диагностике, профилактике и лечению» (№ 122031700094-5_) и при финансовой поддержке гранта Российского научного фонда (№ 21-15-00022)The article was written within the state assignment “Epidemiological monitoring of the population’s health and study of molecular genetic and molecular biological mechanisms underlying the development of common internal diseases in Siberia to improve approaches to their diagnosis, prevention, and treatment” (No. 122031700094-5_) and funded by the Russian Science Foundation grant (No. 21-15-00022)ReferencesFasshauer M., Blüher M. Adipokines in health and disease. Trends Pharmacol. Sci. 2015;36(7):461–470. DOI: 10.1016/j.tips.2015.04.014.Fasshauer M., Blüher M. Adipokines in health and disease. Trends Pharmacol. Sci. 2015;36(7):461–470. DOI: 10.1016/j.tips.2015.04.014.Zhao S., Kusminski C.M., Scherer P.E. Adiponectin, leptin and cardiovascular disorders. Circ. Res. 2021;128(1):136–149. DOI: 10.1161/CIRCRESAHA.120.314458.Zhao S., Kusminski C.M., Scherer P.E. Adiponectin, leptin and cardiovascular disorders. Circ. Res. 2021;128(1):136–149. DOI: 10.1161/CIRCRESAHA.120.314458.Bielecka-Dabrowa A., Bartlomiejczyk M.A., Sakowicz A., Maciejewski M., Banach M. The role of adipokines in the development of arterial stiffness and hypertension. Angiology. 2020;71(8):754–761. DOI: 10.1177/0003319720927203.Bielecka-Dabrowa A., Bartlomiejczyk M.A., Sakowicz A., Maciejewski M., Banach M. The role of adipokines in the development of arterial stiffness and hypertension. Angiology. 2020;71(8):754–761. DOI: 10.1177/0003319720927203.Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casula M., Badimon L. et al. ESC Scientific Document Group. 2019 ESC/ EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal. 2020;1(1):111–188. DOI: 10.1093/eurheartj/ehz455.Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casula M., Badimon L. et al. ESC Scientific Document Group. 2019 ESC/ EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal. 2020;1(1):111–188. DOI: 10.1093/eurheartj/ehz455.Rydén L., Grant P.J., Anker S.D., Berne C., Cosentino F., Danchin N. et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). European Heart Journal. 2013;34(39):3035–3087. DOI: 10.1093/eurheartj/eht108.Rydén L., Grant P.J., Anker S.D., Berne C., Cosentino F., Danchin N. et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). European Heart Journal. 2013;34(39):3035–3087. DOI: 10.1093/eurheartj/eht108.Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):3786. DOI: 10.15829/1560-4071-2020-3-3786.Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):3786. DOI: 10.15829/1560-4071-2020-3-3786.Кокосов А.Н. Хронический необструктивный бронхит. Клиническая медицина. 1999;1:11–16.Кокосов А.Н. Хронический необструктивный бронхит. Клиническая медицина. 1999;1:11–16.Achari A.E., Jain S.K. Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction. Int. J. Mol. Sci. 2017;18:1321. DOI: 10.3390/ijms18061321.Achari A.E., Jain S.K. Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction. Int. J. Mol. Sci. 2017;18:1321. DOI: 10.3390/ijms18061321.Gariballa S., Alkaabi J., Yasin J., Al Essa A. Total adiponectin in overweight and obese subjects and its response to visceral fat loss. BMC Endocr. Disord. 2019;19(1):55. DOI: 10.1186/s12902-019-0386-z.Gariballa S., Alkaabi J., Yasin J., Al Essa A. Total adiponectin in overweight and obese subjects and its response to visceral fat loss. BMC Endocr. Disord. 2019;19(1):55. DOI: 10.1186/s12902-019-0386-z.Liu C., Feng X., Li Q., Wang Y., Li Q., Hua M. Adiponectin, TNF-α and inflammatory cytokines and risk of type 2 diabetes: A systematic review and meta-analysis. Cytokine. 2016;86:100–109. DOI: 10.1016/j.cyto.2016.06.028.Liu C., Feng X., Li Q., Wang Y., Li Q., Hua M. Adiponectin, TNF-α and inflammatory cytokines and risk of type 2 diabetes: A systematic review and meta-analysis. Cytokine. 2016;86:100–109. DOI: 10.1016/j.cyto.2016.06.028.Lindberg S., Jensen J.S., Pedersen S.H., Galatius S., Frystyk J., Flyvbjerg A. et al. Low adiponectin levels and increased risk of type 2 diabetes in patients with myocardial infarction. Diabetes Care. 2014;37:3003–3008.Lindberg S., Jensen J.S., Pedersen S.H., Galatius S., Frystyk J., Flyvbjerg A. et al. Low adiponectin levels and increased risk of type 2 diabetes in patients with myocardial infarction. Diabetes Care. 2014;37:3003–3008.Kou H., Deng J., Gao D., Song A., Han Z., Wei J. et al. Relationship among adiponectin, insulin resistance and atherosclerosis in non-diabetic hypertensive patients and healthy adults. Clin. Exp. Hypertens. 2018;40(7):656–663. DOI: 10.1080/10641963.2018.1425414.Kou H., Deng J., Gao D., Song A., Han Z., Wei J. et al. Relationship among adiponectin, insulin resistance and atherosclerosis in non-diabetic hypertensive patients and healthy adults. Clin. Exp. Hypertens. 2018;40(7):656–663. DOI: 10.1080/10641963.2018.1425414.Kim D.H., Kim C., Ding E.L., Townsend M.K., Lipsitz L.A. Adiponectin levels and the risk of hypertension: a systematic review and meta-analysis. Hypertension. 2013;62(1):27–32. DOI: 10.1161/HYPERTENSIONAHA.113.01453.Kim D.H., Kim C., Ding E.L., Townsend M.K., Lipsitz L.A. Adiponectin levels and the risk of hypertension: a systematic review and meta-analysis. Hypertension. 2013;62(1):27–32. DOI: 10.1161/HYPERTENSIONAHA.113.01453.Doumatey A.P., Bentley A.R., Zhou J., Huang H., Adeyemo A., Rotimi C.N. Paradoxical hyperadiponectinemia is associated with the metabolically healthy obese (MHO) phenotype in African Americans. J. Endocrinol. Metab. 2012;2(2):51–65. DOI: 10.4021/jem95W.Doumatey A.P., Bentley A.R., Zhou J., Huang H., Adeyemo A., Rotimi C.N. Paradoxical hyperadiponectinemia is associated with the metabolically healthy obese (MHO) phenotype in African Americans. J. Endocrinol. Metab. 2012;2(2):51–65. DOI: 10.4021/jem95W.Kobayashi H., Ouchi N., Kihara S., Walsh K., Kumada M., Abe Y. et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ. Res. 2004;94(4):27–31. DOI: 10.1161/01.RES.0000119921.86460.37.Kobayashi H., Ouchi N., Kihara S., Walsh K., Kumada M., Abe Y. et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ. Res. 2004;94(4):27–31. DOI: 10.1161/01.RES.0000119921.86460.37.Woodward L., Akoumianakis I., Antoniades C. Unravelling the adiponectin paradox: Novel roles of adiponectin in the regulation of cardiovascular disease. Br. J. Pharmacol. 2017;174:4007–4020. DOI: 10.1111/bph.13619.Woodward L., Akoumianakis I., Antoniades C. Unravelling the adiponectin paradox: Novel roles of adiponectin in the regulation of cardiovascular disease. Br. J. Pharmacol. 2017;174:4007–4020. DOI: 10.1111/bph.13619.Wannamethee S.G., Whincup P., Lennon L., Sattar N. Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch. Intern. Med. 2007;167:1510–1517. DOI: 10.1001/archinte.167.14.1510.Wannamethee S.G., Whincup P., Lennon L., Sattar N. Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch. Intern. Med. 2007;167:1510–1517. DOI: 10.1001/archinte.167.14.1510.McEntegart M.B., Awede B., Petrie M.C., Sattar N., Dunn F.G., Macfarlane N.G. et al. Increase in serum adiponectin concentration in patients with heart failure and cachexia: Relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur. Heart J. 2007;28:829–835. DOI: 10.1093/eurheartj/ehm033.McEntegart M.B., Awede B., Petrie M.C., Sattar N., Dunn F.G., Macfarlane N.G. et al. Increase in serum adiponectin concentration in patients with heart failure and cachexia: Relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur. Heart J. 2007;28:829–835. DOI: 10.1093/eurheartj/ehm033.Dornbush S., Aeddula N.R. Physiology, leptin. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2021.Dornbush S., Aeddula N.R. Physiology, leptin. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2021.Khazaei M., Tahergorabi Z. Leptin and its cardiovascular effects: Focus on angiogenesis. Advanced Biomedical Research. 2015;4(1):79. DOI: 10.4103/2277-9175.156526.Khazaei M., Tahergorabi Z. Leptin and its cardiovascular effects: Focus on angiogenesis. Advanced Biomedical Research. 2015;4(1):79. DOI: 10.4103/2277-9175.156526.Fried S.K., Ricci M.R., Russell C.D., Laferrère B. Regulation of leptin production in humans. J. Nutr. 2000;130(12):3127S–3131S. DOI: 10.1093/jn/130.12.3127S.Fried S.K., Ricci M.R., Russell C.D., Laferrère B. Regulation of leptin production in humans. J. Nutr. 2000;130(12):3127S–3131S. DOI: 10.1093/jn/130.12.3127S.Katsiki N., Mikhailidis D.P., Banach M. Leptin, cardiovascular diseases and type 2 diabetes mellitus review-article. Acta Pharmacol. Sin. 2018;39:1176–1188. DOI: 10.1038/aps.2018.40.Katsiki N., Mikhailidis D.P., Banach M. Leptin, cardiovascular diseases and type 2 diabetes mellitus review-article. Acta Pharmacol. Sin. 2018;39:1176–1188. DOI: 10.1038/aps.2018.40.Marchelek-Mysliwiec M., Wisniewska M., Nowosiad-Magda M., Safranow K., Kwiatkowska E., Banach B. et al. Association between plasma concentration of klotho protein, osteocalcin, leptin, adiponectin, and bone mineral density in patients with chronic kidney disease. Horm. Metab. Res. 2018;50:816–821. DOI: 10.1055/a-0752-4615.Marchelek-Mysliwiec M., Wisniewska M., Nowosiad-Magda M., Safranow K., Kwiatkowska E., Banach B. et al. Association between plasma concentration of klotho protein, osteocalcin, leptin, adiponectin, and bone mineral density in patients with chronic kidney disease. Horm. Metab. Res. 2018;50:816–821. DOI: 10.1055/a-0752-4615.Wang J.S., Lee W.J., Lee I.T., Lin S.Y., Lee W.L., Liang K.W. et al. Association between serum adipsin levels and insulin resistance in subjects with various degrees of glucose intolerance. J. Endocr. Soc. 2018;3(2):403–410. DOI: 10.1210/js.2018-00359.Wang J.S., Lee W.J., Lee I.T., Lin S.Y., Lee W.L., Liang K.W. et al. Association between serum adipsin levels and insulin resistance in subjects with various degrees of glucose intolerance. J. Endocr. Soc. 2018;3(2):403–410. DOI: 10.1210/js.2018-00359.Василенко М.А., Кириенкова Е.В., Скуратовская Д.А., Затолокин П.А., Миронюк Н.И., Литвинова Л.С. Роль продукции адипсина и лептина в формировании инсулинорезистентности у больных абдоминальным ожирением. Доклады Академии наук. 2017;475(3):336–341. DOI: 10.7868/S0869565217210228.Василенко М.А., Кириенкова Е.В., Скуратовская Д.А., Затолокин П.А., Миронюк Н.И., Литвинова Л.С. Роль продукции адипсина и лептина в формировании инсулинорезистентности у больных абдоминальным ожирением. Доклады Академии наук. 2017;475(3):336–341. DOI: 10.7868/S0869565217210228.Hertle E., Arts I.C., van der Kallen C.J., Feskens E.J., Schalkwijk C.G., Stehouwer C.D. et al. The alternative complement pathway is longitudinally associated with adverse cardiovascular outcomes. Thromb. Haemost. 2016;115(2):446–457. DOI: 10.1160/TH15-05-0439.Hertle E., Arts I.C., van der Kallen C.J., Feskens E.J., Schalkwijk C.G., Stehouwer C.D. et al. The alternative complement pathway is longitudinally associated with adverse cardiovascular outcomes. Thromb. Haemost. 2016;115(2):446–457. DOI: 10.1160/TH15-05-0439.Song N.J., Kim S., Jang B.H., Chang S.H., Yun U.J., Park K.M. et al. Molecule-induced complement factor D (adipsin) promotes lipid accumulation and adipocyte differentiation. PLoS One. 2016;11(9):e0162228. DOI: 10.1371/journal.pone.0162228.Song N.J., Kim S., Jang B.H., Chang S.H., Yun U.J., Park K.M. et al. Molecule-induced complement factor D (adipsin) promotes lipid accumulation and adipocyte differentiation. PLoS One. 2016;11(9):e0162228. DOI: 10.1371/journal.pone.0162228.Jalal D., Renner B., Laskowski J., Stites E., Cooper J., Valente K. et al. Endothelial microparticles and systemic complement activation in patients with chronic kidney disease. J. Am. Heart Assoc. 2018;7(14):e007818. DOI: 10.1161/JAHA.117.007818.Jalal D., Renner B., Laskowski J., Stites E., Cooper J., Valente K. et al. Endothelial microparticles and systemic complement activation in patients with chronic kidney disease. J. Am. Heart Assoc. 2018;7(14):e007818. DOI: 10.1161/JAHA.117.007818.Buonafine M., Martinez-Martinez E., Jaisser F. More than a simple biomarker: the role of NGAL in cardiovascular and renal diseases. Clin. Sci. (London). 2018;132(9):909–923. DOI: 10.1042/CS20171592.Buonafine M., Martinez-Martinez E., Jaisser F. More than a simple biomarker: the role of NGAL in cardiovascular and renal diseases. Clin. Sci. (London). 2018;132(9):909–923. DOI: 10.1042/CS20171592.Cabedo Martinez A.I., Weinhäupl K., Lee W.K., Wolff N.A., Storch B., Żerko S. et al. Biochemical and structural characterization of the interaction between the siderocalin NGAL/ LCN2 (neutrophil gelatinase-associated lipocalin/lipocalin 2) and the N-terminal domain of its endocytic receptor SLC22A17. J. Biol. Chem. 2016;291(6):2917–2930. DOI: 10.1074/jbc.M115.685644.Cabedo Martinez A.I., Weinhäupl K., Lee W.K., Wolff N.A., Storch B., Żerko S. et al. Biochemical and structural characterization of the interaction between the siderocalin NGAL/ LCN2 (neutrophil gelatinase-associated lipocalin/lipocalin 2) and the N-terminal domain of its endocytic receptor SLC22A17. J. Biol. Chem. 2016;291(6):2917–2930. DOI: 10.1074/jbc.M115.685644.Chella Krishnan K., Sabir S., Shum M., Meng Y., Acín-Pérez R., Lang J.M. et al. Sex-specific metabolic functions of adipose lipocalin-2. Mol. Metab. 2019;30:30–47. DOI: 10.1016/j.molmet.2019.09.009.Chella Krishnan K., Sabir S., Shum M., Meng Y., Acín-Pérez R., Lang J.M. et al. Sex-specific metabolic functions of adipose lipocalin-2. Mol. Metab. 2019;30:30–47. DOI: 10.1016/j.molmet.2019.09.009.Chong J.J.H., Prince R.L., Thompson P.L., Thavapalachandran S., Ooi E., Devine A. et al. Association between plasma neutrophil gelatinase-associated lipocalin and cardiac disease hospitalizations and deaths in older women. J. Am. Heart Assoc. 2019;8(1):e011028. DOI: 10.1161/JAHA.118.011028.Chong J.J.H., Prince R.L., Thompson P.L., Thavapalachandran S., Ooi E., Devine A. et al. Association between plasma neutrophil gelatinase-associated lipocalin and cardiac disease hospitalizations and deaths in older women. J. Am. Heart Assoc. 2019;8(1):e011028. DOI: 10.1161/JAHA.118.011028.Cruz D.N., Gaiao S., Maisel A., Ronco C., Devarajan P. Neutrophil Gelatinase-Associated Lipocalin as a Biomarker of Cardiovascular Disease: A Systematic Review. Clin. Chem. Lab. Med. 2012;50:1533–1545. DOI: 10.1515/cclm-2012-0307.Cruz D.N., Gaiao S., Maisel A., Ronco C., Devarajan P. Neutrophil Gelatinase-Associated Lipocalin as a Biomarker of Cardiovascular Disease: A Systematic Review. Clin. Chem. Lab. Med. 2012;50:1533–1545. DOI: 10.1515/cclm-2012-0307.Wang L.K., Wang H., Wu X.L., Shi L., Yang R.M., Wang Y.C. Relationships among resistin, adiponectin, and leptin and microvascular complications in patients with type 2 diabetes mellitus. J. Int. Med. Res. 2020;48(4):300060519870407. DOI: 10.1177/0300060519870407.Wang L.K., Wang H., Wu X.L., Shi L., Yang R.M., Wang Y.C. Relationships among resistin, adiponectin, and leptin and microvascular complications in patients with type 2 diabetes mellitus. J. Int. Med. Res. 2020;48(4):300060519870407. DOI: 10.1177/0300060519870407.Niaz S., Latif J., Hussain S. Serum resistin: A possible link between inflammation, hypertension and coronary artery disease. Pak. J. Med. Sci. 2019;35(3):641–646. DOI: 10.12669/pjms.35.3.274.Niaz S., Latif J., Hussain S. Serum resistin: A possible link between inflammation, hypertension and coronary artery disease. Pak. J. Med. Sci. 2019;35(3):641–646. DOI: 10.12669/pjms.35.3.274.Jiang Y., Lu L., Hu Y., Li Q., An C., Yu X. et al. Resistin induces hypertension and insulin resistance in mice via a TLR4-dependent pathway. Sci. Rep. 2016;6:22193. DOI: 10.1038/srep22193.Jiang Y., Lu L., Hu Y., Li Q., An C., Yu X. et al. Resistin induces hypertension and insulin resistance in mice via a TLR4-dependent pathway. Sci. Rep. 2016;6:22193. DOI: 10.1038/srep22193.Chen C., Jiang J., Lü J.M., Chai H., Wang X., Lin P.H. et al. Resistin decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 2010;299(1):H193–201. DOI: 10.1152/ajpheart.00431.2009.Chen C., Jiang J., Lü J.M., Chai H., Wang X., Lin P.H. et al. Resistin decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 2010;299(1):H193–201. DOI: 10.1152/ajpheart.00431.2009.Axelsson J., Bergsten A., Qureshi A.R., Heimbürger O., Bárány P., Lönnqvist F. et al. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int. 2006;69(3):596–604. DOI: 10.1038/sj.ki.5000089.Axelsson J., Bergsten A., Qureshi A.R., Heimbürger O., Bárány P., Lönnqvist F. et al. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int. 2006;69(3):596–604. DOI: 10.1038/sj.ki.5000089.Dan S., Aditya P., Banerjee P., Bal C., Roy H., Banerjee I. Effect of chronic kidney disease on serum resistin level. Niger J. Clin. Pract. 2014;17(6):735–738. DOI: 10.4103/1119-3077.144387.Dan S., Aditya P., Banerjee P., Bal C., Roy H., Banerjee I. Effect of chronic kidney disease on serum resistin level. Niger J. Clin. Pract. 2014;17(6):735–738. DOI: 10.4103/1119-3077.144387.Liu G., Deng Y., Sun L., Ye X., Yao P., Hu Y. et al. Elevated plasma tumor necrosis factor-α receptor 2 and resistin are associated with increased incidence of kidney function decline in Chinese adults. Endocrine. 2016;52(3):541–549. DOI: 10.1007/s12020-015-0807-3.Liu G., Deng Y., Sun L., Ye X., Yao P., Hu Y. et al. Elevated plasma tumor necrosis factor-α receptor 2 and resistin are associated with increased incidence of kidney function decline in Chinese adults. Endocrine. 2016;52(3):541–549. DOI: 10.1007/s12020-015-0807-3.Pérez-Bautista O., Montaño M., Pérez-Padilla R., Zúñiga-Ramos J., Camacho-Priego M., Barrientos-Gutiérrez T. et al. Women with COPD by biomass show different serum profile of adipokines, incretins, and peptide hormones than smokers. Respir. Res. 2018;19(1):239. DOI: 10.1186/s12931-018-0943-4.Pérez-Bautista O., Montaño M., Pérez-Padilla R., Zúñiga-Ramos J., Camacho-Priego M., Barrientos-Gutiérrez T. et al. Women with COPD by biomass show different serum profile of adipokines, incretins, and peptide hormones than smokers. Respir. Res. 2018;19(1):239. DOI: 10.1186/s12931-018-0943-4.Vecchiola A., García K., González-Gómez L.M., Tapia-Castillo A., Artigas R., Baudrand R. et al. Plasminogen activator inhibitor-1 and adiponectin are associated with metabolic syndrome components. Am. J. Hypertens. 2022;35(4):311–318. DOI: 10.1093/ajh/hpab138.Vecchiola A., García K., González-Gómez L.M., Tapia-Castillo A., Artigas R., Baudrand R. et al. Plasminogen activator inhibitor-1 and adiponectin are associated with metabolic syndrome components. Am. J. Hypertens. 2022;35(4):311–318. DOI: 10.1093/ajh/hpab138.

The authors declare that there are no conflicts of interest present.